KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Gains from Investment Securities (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Gains from Investment Securities for 15 consecutive years, with -$7.8 million as the latest value for Q2 2025.

  • On a quarterly basis, Gains from Investment Securities fell 116.67% to -$7.8 million in Q2 2025 year-over-year; TTM through Jun 2025 was $300000.0, a 367.86% increase, with the full-year FY2025 number at $3.0 million, down 96.98% from a year prior.
  • Gains from Investment Securities was -$7.8 million for Q2 2025 at Bio-Rad Laboratories, down from $7.9 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $96.2 million in Q3 2022 to a low of -$55.3 million in Q3 2021.
  • A 5-year average of $11.3 million and a median of $8.9 million in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: plummeted 233.03% in 2021, then soared 12515.43% in 2022.
  • Bio-Rad Laboratories' Gains from Investment Securities stood at $162000.0 in 2021, then skyrocketed by 12515.43% to $20.4 million in 2022, then tumbled by 149.51% to -$10.1 million in 2023, then soared by 64.42% to -$3.6 million in 2024, then crashed by 116.67% to -$7.8 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Gains from Investment Securities are -$7.8 million (Q2 2025), $7.9 million (Q1 2025), and -$3.6 million (Q2 2024).